Delivery Order SPE2DB22D1202-SPE2DB25FVKY3
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,372.49 to AmerisourceBergen Drug Corp for the supply of Xyosted 100 mg/0.5 mL auto-injector units. This is a firm fixed price, competitively awarded contract with no set-aside designation, completed on August 19, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, which serves as the company's place of performance for this federal procurement. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector units valued at $1,813.90. This firm fixed-price delivery order is scheduled for completion by August 4, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's competitive capability...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Xyosted 75 mg/0.5 mL auto-injector vials valued at $3,609.99 with completion targeted for August 19, 2025. This competitively awarded, non-set-aside delivery order utilizes firm fixed price terms and is performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen Drug Corp's...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Xyosted 100 mg/0.5 ml auto-injector vials with a ceiling value of $1,074.75 and an ultimate completion date of August 12, 2025. This firm fixed-price delivery order is unclassified as a set-aside contract and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of the company's role as a...
- The Defense Logistics Agency awarded a delivery order valued at $1,388.60 to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Xyosted 100 mg/0.5 ml auto-injector (0.5 ml). This competitive award, utilizing firm fixed pricing with no set-aside designation, is scheduled for completion by August 14, 2025, with performance taking place at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and...
- The Defense Logistics Agency awarded a delivery order valued at $1,655.80 to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 mL auto-injector units on July 28, 2025, with completion expected by July 29, 2025. This delivery order represents a firm fixed-price purchase with no set-aside designation, indicating the award was made through open competition. The pharmaceutical product will be delivered to the place of performance located in Conshohocken, Pennsylvania, where AmerisourceBergen...
- The Defense Logistics Agency awarded a $2,150.75 delivery order to AmerisourceBergen Drug Corp for the supply of Xyosted 100 mg/0.5 ml auto-injector units. This competitively awarded, non-set-aside contract carries a firm fixed price structure with an ultimate completion date of August 4, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's broader pharmaceutical supply...
- The Defense Logistics Agency awarded a $1,629.66 delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Xyosted 75 mg/0.5 mL auto-injector units. This firm fixed-price delivery order, with an ultimate completion date of August 12, 2025, represents a small-value pharmaceutical procurement fulfilled through performance in Conshohocken, Pennsylvania. The award was made competitively with no set-aside designation and is classified as a child contract under a larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector units valued at $2,440.29 with a firm fixed price. This is a non-set-aside, competitively awarded delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The product will be performed at AmerisourceBergen's...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order for Xyosted 75 mg/0.5 mL auto-injector vials by the Defense Logistics Agency on September 9, 2025. The contract carries a ceiling value of $3,766.19 with a firm fixed-price structure and an ultimate completion date of September 10, 2025. This is a non-set-aside award issued under a competitive procurement process, reflecting the company's demonstrated...
- SPE2DB22D1202Indefinite Delivery Contract
- SPE2DB22D1202-SPE2DB25FVKY3Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,667.86 to AmerisourceBergen Drug Corp for Xyosted 75 mg/0.5 ml auto-injector supplies. This firm fixed-price, non-set-aside contract was awarded on September 10, 2025, with an ultimate completion date of September 11, 2025. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order represents a continuation of the vendor's extensive federal pharmaceutical supply relationship with DLA. This award is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a wide range of pharmaceutical products and medical supplies to military healthcare programs worldwide, including specialty medications, brand-name and generic drugs, and medical devices across multiple therapeutic domains. AmerisourceBergen's demonstrated capability to compete successfully for federal medical procurement and its established relationship with the Defense Health Agency and other government healthcare systems positions it as a critical vendor for supporting military medical supply chain requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.7k | 9/10/25 |